FORMYCON AG overview

EQS-News: Formycon AG / Key word(s): Annual Report/Annual Results Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // March 27, 2025 Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position Group revenue exceeds...

EQS-News: Formycon AG / Key word(s): Conference/Annual Report Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 24.03.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // March 24, 2025 Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor...

EQS-News: Formycon AG / Key word(s): Product Launch FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union 03.03.2025 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // March 3, 2025 FYB202/Otulfi ® (u stekinumab-aauz ) , a biosimilar to Stelara ® , launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and...

EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 25, 2025 Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea ® , under the brand name AHZANTIVE ® FYB203 (aflibercept) approved in the UK...

EQS-News: Formycon AG / Key word(s): Scientific publication Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 20, 2025 Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of...

EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon AG informs about recent developments in various biosimilar projects and invites to conference call 17.02.2025 / 09:27 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 17, 2025 Formycon AG informs about recent developments in various biosimilar projects and invites to conference call Formycon continues FYB206 development without Phase III trial and thus takes pioneering role among...

EQS-Ad-hoc: Formycon AG / Key word(s): Study/Statement Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 17-Feb-2025 / 08:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Disclosure of inside information according to Article 17...

EQS-News: Formycon AG / Key word(s): Agreement Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region 05.02.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 05, 2025 Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea ® biosimilar FYB203/AHZANTIVE ® in the Asia-Pacific Region...